anti-CD19 CAR NK-cell therapy (Washington University in St Louis)

N/A

Report date: 2025/03/14 16:48:41

Base Information

Drug Nameanti-CD19 CAR NK-cell therapy (Washington University in St Louis)
Drug Alias Name19-CAR-ML NK cell Therapy (Washington University in St Louis)19-CAR-ML NK cells
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphomaLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesWashington University
China Registration ClassN/A

Develop Information

Active CompaniesWugen Inc
Inactive CompaniesN/A
Active IndicationsLymphomaLeukemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A